April 13, 2022
RegMed Investors’ (RMi) pre-open: tread lightly by measuring and analyzing sector equities carefully
April 12, 2022
RegMed Investors’ (RMi) pre-open: CPI +8.5% inflation release clouds the markets
April 11, 2022
RegMed Investors’ (RMi) pre-open: Share pricing risk is weighted by week’s economics and lack of value catalysts
April 8, 2022
RegMed Investors’ (RMi) pre-open: be bold for the oversold
April 7, 2022
RegMed Investors’ (RMi) pre-open: sentiment is not providing a cushion to buying cell and gene therapy sector equities
April 6, 2022
RegMed Investors’ (RMi) pre-open: hanging on for cell and gene sector share pricing life
April 5, 2022
RegMed Investors’ (RMi) pre-open: upside jeopardy as the lack of substantiating news, I believe inhibits the sector
April 4, 2022
RegMed Investors’ (RMi) pre-open: conflicting signals?
March 31, 2022
RegMed Investors’ (RMi) pre-open: uncertainty as March and Q1 come to a close
March 30, 2022
RegMed Investors’ (RMi) pre-open: war and peace headlines versus the pricing of the sector
March 29, 2022
RegMed Investors’ (RMi) pre-open: the cell and gene therapy sector is caught in a cycle of unpredictability
March 28, 2022
RegMed Investors’ (RMi) pre-open: what’s the problem with share pricing?
March 25, 2022
RegMed Investors’ (RMi) pre-open: a week of boom and bust
March 24, 2022
RegMed Investors’ (RMi) pre-open: mirror, mirror on the wall; will the sector’s upside stand tall?
March 24, 2022
RegMed Investors’ (RMi) pre-open: mirror, mirror on the wall; will the sector’s upside stand tall?
March 23, 2022
RegMed Investors’ (RMi) pre-open: the reality of the volatile share pricing cycle
March 22, 2022
RegMed Investors’ (RMi) pre-open: exposure to risk slips and slides
March 21, 2022
RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk
March 18, 2022
RegMed Investors’ (RMi) pre-open: Key word, anticipate
March 17, 2022
RegMed Investors’ (RMi) pre-open: don’t get too excited
March 16, 2022
RegMed Investors’ (RMi) pre-open: the “always” question, what’s sustainable
March 15, 2022
RegMed Investors’ (RMi) pre-open: cell and gene therapy sector, not lookin’ good
March 14, 2022
RegMed Investors’ (RMi) pre-open: the phoenix rises from the shares as do share pricings after being burned to a crisp
March 11, 2022
RegMed Investors’ (RMi) pre-open: dramatic market and sector moves are still questionable
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.